检索结果-内蒙古大学图书馆

Emerging Therapeutic Approaches to Hepatocellular Carcinoma

ANNALS OF SURGICAL ONCOLOGY 2010年第5期17卷 1217-1218页

作者： Pawlik, Timothy M. Johns Hopkins Univ Sch Med Dept Surg Baltimore MD 21205 USA

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide, and its incidence is dramatically increasing in the United States. Unlike many other malignancies, treatment of HCC often involves management of two disease processes: liver cancer and cirrhosis. In addition to tumor-specific factors such as tumor size, number, and location, the surgeon also has to consider liver specific factors such as degree of fibrosis/ cirrhosis, extent of portal hypertension, and the size of the future liver remnant. As such, therapy for HCC is complex and can involve resection, transplantation, interventional radiology-based liver-directed therapies, and emerging systemic chemotherapeutic and targeted agents. To successfully treat this group of patients, surgical oncologists should be aware of the many and varied approaches to treating patients with HCC. Specifically, surgical oncologists need to know not only how to select patients and perform hepatic resection in appropriate patients with HCC, but also be familiar with the controversy surrounding management of early HCC and identify those factors that may make one therapeutic modality preferable compared with others. In addition, surgical oncologists need to be familiar with the role of intra-arterial regional therapy as "destination" therapy for unresectable HCC, as well as bridge therapy before transplantation/resection. Finally, surgical oncologists need to be aware of the emerging role of systemic chemotherapy for stage IV HCC, as well as its potential future role as adjuvant therapy. In this issue of Annals of Surgical Oncology, a series of review articles have been solicited to provide evidence-based data to equip the practicing surgical oncologist with the knowledge to understand these complex treatment issues.

关键词： Hepatocellular Cancer Liver Cirrhosis Portal Hypertension adjuvant therapy Awareness human-centered computing

来源：评论

学校读者我要写书评

暂无评论

Liver Transplantation for Hepatocellular Carcinoma

引用

CANCER CONTROL 2010年第2期17卷 83-86页

作者： Alsina, Angel E. Tampa Gen Hosp LifeLink HealthCare Inst Dept Surg Tampa FL 33606 USA Tampa Gen Hosp LifeLink HealthCare Inst Dept Liver Transplantat Tampa FL 33606 USA Tampa Gen Hosp LifeLink HealthCare Inst Dept Hepatobiliary Surg Tampa FL 33606 USA

Background: The treatment of hepatocellular carcinoma (HCC) is challenging, but transplantation of the liver has emerged as one of the options in the therapeutic armamentarium against this disease. Methods: This article reviews the changing criteria for patient eligibility for liver transplantation for HCC and presents an initial evaluation of institutional treatment outcomes for this treatment modality. A method for evaluating prognosis is also described. Results: Patients are considered for liver transplantation if they meet the Milan criteria for eligibility or a UCSF-attributed expansion of these criteria that includes the "rule of 7," whereby the sum of the size of the largest nodule plus the total number of nodules cannot exceed 7. Preliminary institutional experience suggests a tumor recurrence rate of 11% in 91 patients with HCC who received liver transplants between 1996 and 2008. Conclusions: Liver transplantation offers an opportunity for long-term survival in patients with HCC and chronic cirrhosis whose tumor cannot be resected. Criteria for patient selection for this modality of treatment continue to be upgraded and refined.

关键词： Modality Patient Selection human-centered computing eligibility Treatment Outcome Liver Transplantation Repetition rate

来源：评论

学校读者我要写书评

暂无评论

Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation

引用

CANCER CELL 2010年第3期17卷 286-297页

作者： He, Guobin Yu, Guann-Yi Temkin, Vladislav Ogata, Hisanobu Kuntzen, Christian Sakurai, Toshiharu Sieghart, Wolfgang Peck-Radosavljevic, Markus Leffert, Hyam L. Karin, Michael Univ Calif San Diego Sch Med Lab Gene Regulat & Signal Transduct La Jolla CA 92093 USA Univ Calif San Diego Sch Med Hepatocyte Growth Control & Stem Cell Lab La Jolla CA 92093 USA Kyoto Univ Grad Sch Med Dept Clin Mol Biol Sakyo Ku Kyoto 6068507 Japan Med Univ Vienna Div Gastroenterol Hepatol Dept Internal Med 3 A-1090 Vienna Austria

The NF-kappa B activating kinase IKK beta suppresses early chemically induced liver tumorigenesis by inhibiting hepatocyte death and compensatory IKK beta's role in late tumor promotion and progression, we developed a transplant system that allows initiated mouse hepatocytes to form hepatocellular carcinomas (HCC) in host liver after along latency. Deletion of IKK beta long after initiation accelerated HCC development and enhanced proliferation of tumor initiating cells. These effects of IKK beta/NF-kappa B were cell autonomous and correlated with increased accumulation of reactive oxygen species that led to JNK and STAT3 activation. Hepatocyte-specific STAT3 ablation prevented HCC development. The negative crosstalk between NF-kappa B and STAT3, which is also evident in human HCC, is a critical regulator of liver cancer development and progression.

关键词： progressions Hepatocytes Cancer of Liver MAPK8 gene Tumor Promotion NF-kappa B human-centered computing

来源：评论

学校读者我要写书评

暂无评论

Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA

引用

NATURE CELL BIOLOGY 2010年第4期12卷 390-U208页

作者： Ding, Jie Huang, Shenglin Wu, Shunquan Zhao, Yingjun Liang, Linhui Yan, Mingxia Ge, Chao Yao, Jian Chen, Taoyang Wan, Dafang Wang, Hongyang Gu, Jianren Yao, Ming Li, Jinjun Tu, Hong He, Xianghuo Shanghai Jiao Tong Univ Sch Med Shanghai Canc Inst State Key Lab Oncogenes & Related Genes Shanghai 200032 Peoples R China Fudan Univ Shanghai Med Coll Shanghai 200032 Peoples R China Shanghai Jiao Tong Univ Sch Med Shanghai Canc Inst Dept Expt Pathol Shanghai 200032 Peoples R China Qi Dong Liver Canc Inst Qi Dong 226200 Jiangsu Peoples R China

Recurrent chromosomal aberrations are often observed in hepatocellular carcinoma (HCC), but little is known about the functional non-coding sequences, particularly microRNAs (miRNAs), at the chromosomal breakpoints in HCC. Here we show that 22 miRNAs are often amplified or deleted in HCC. MicroRNA-151 (miR-151), a frequently amplified miRNA on 8q24.3, is correlated with intrahepatic metastasis of HCC. We further show that miR-151, which is often expressed together with its host gene FAK, encoding focal adhesion kinase, significantly increases HCC cell migration and invasion in vitro and in vivo, mainly through miR-151-5p, but not through miR-151-3p. Moreover, miR-151 exerts this function by directly targeting RhoGDIA, a putative metastasis suppressor in HCC, thus leading to the activation of Rac1, Cdc42 and Rho GTPases. In addition, miR-151 can function synergistically with FAK to enhance HCC cell motility and spreading. Thus, our findings indicate that chromosome gain of miR-151 is a crucial stimulus for tumour invasion and metastasis of HCC.

关键词： rho GTP-Binding Proteins MicroRNAs Focal Adhesion Kinase 1 Tumor Cell Invasion Gain Cell Locomotion metastasis Neoplasm Metastasis Focal Adhesion Protein-Tyrosine Kinases Neoplastic Cell human-centered computing Cell Migration non-specific protein-tyrosine kinase

来源：评论

学校读者我要写书评

暂无评论

Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial

引用

ANNALS OF SURGICAL ONCOLOGY 2010年第12期17卷 3137-3144页

作者： Xia, Yong Qiu, Yinghe Li, Jun Shi, Lehua Wang, Kui Xi, Tao Shen, Feng Yan, Zhenlin Wu, Mengchao Second Mil Med Univ Dept Comprehens Treatment 1 Eastern Hepatobiliary Surg Hosp Shanghai Peoples R China

Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection. To date, adjuvant chemotherapy or other adjuvant modalities have not been proven effective in preventing or delaying recurrence. The aim of this prospective randomized study was to evaluate the effectiveness of capecitabine as a postoperative adjuvant regimen in inhibiting the recurrence of HCC. Between August 2003 and January 2005, 60 HCC patients who underwent curative resection were randomized into a capecitabine (n = 30) or a control (n = 30) group. The capecitabine group received 4-6 episodes of capecitabine treatment plus routine supportive care. Each episode consisted of 2 weeks of capecitabine followed by 1-week rest. The control group received routine supportive care only. The follow-up was 4-65 months (median: 47.5 months). Cancer recurred in 16 patients (53.3%) in the capecitabine group and in 23 patients (76.7%) in the control group. The median time to recurrence (TTR) was 40.0 months (95% confidence interval [95% CI], 31.0-49.2 months) and 20.0 months (95% CI, 12.8-27.2 months) in the capecitabine and control groups, respectively (P = 0.046). The 5-year overall survival rate was 62.5% and 39.8% in the capecitabine group and control group, respectively (P = .216). Adverse reactions to capecitabine were generally mild and included nausea, vomiting, diarrhea, and decreased white blood cell and/or platelet counts. Postoperative adjuvant therapy with capecitabine is well tolerated, postpones the recurrence of HCC, and reduces the risk of tumor recurrence. In addition, it is likely to improve postoperative survival.

关键词： Hepatocellular Cancer ectomy adjuvant therapy Capecitabine Control Groups human-centered computing Recurrent Neoplasm Relapse

来源：评论

学校读者我要写书评

暂无评论

Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era

引用

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS 2010年第5期210卷 727-734页

作者： Levi, David M. Tzakis, Andreas G. Martin, Paul Nishida, Seigo Island, Eddie Moon, Jang Selvaggi, Gennaro Tekin, Akin Madrazo, Beatrice L. Narayanan, Govindarajan Garcia, Monica T. Feun, Lynn G. Tryphonopoulos, Panagiotis Skartsis, Nikolaos Livingstone, Alan S. Univ Miami DeWitt Daughtry Family Dept Surg Miller Sch Med Miami FL 33136 USA Univ Miami Miller Sch Med Miami Transplant Inst Miami FL 33136 USA Univ Miami Miller Sch Med Dept Med Miami FL 33136 USA Univ Miami Miller Sch Med Dept Radiol Miami FL 33136 USA Univ Miami Miller Sch Med Dept Pathol Miami FL 33136 USA

BACKGROUND: Since March 2002, the United Network for Organ Sharing liver allocation policy has given extra priority to patients with hepatocellular carcinoma (HCC) who meet specific medical criteria. This study reviews our experience with liver transplantation for HCC under this system. STUDY DESIGN: Between March 2002 and April 2009, 244 patients with HCC underwent primary liver or liver-kidney transplantation under the current allocation system at the University of Miami. Outcomes including HCC recurrence-free survival (RFS) and patient survival (PS) were assessed retrospectively. Clinical variables that predicted outcomes were analyzed. RESULTS: The median time from listing to transplantation was 48 days. The median follow-up was 27.4 months, with an observed recurrence rate of 10.7%. The RFS rates at 1, 3, and 5 years after transplantation were 96.0%, 89.0%, and 83.6%, respectively. The PS rates at 1, 3, and 5 years after transplantation were 86.3%, 71.5%, and 61.7%, respectively. Among patients diagnosed with T2 HCC, a trend toward improved RFS was observed for those who received preoperative ablative therapy;PS was similar (p > 0.05). Outcomes (RFS and PS) for patients with T3 HCC were similar to those in patients with T2 HCC (p > 0.05). Patients with an alpha-fetoprotein >100 ng/mL had all RFS that was inferior to that in patients with an alpha-fetoprotein <= 100 ng/mL (p < 0.0001). CONCLUSIONS: Under the current allocation system, transplantation for HCC results in excellent RFS;PS depends Oil factors other than HCC;the value of preoperative ablative therapy for patients with T2 HCC is uncertain;the current criteria could be expanded to include selected patients with T3 HCC;and an elevated AFP level is associated with an increased risk of HCC recurrence after transplantation. (J Am Coll Surg 2010;210:727-736. (C) 2010 by the American College of Surgeons)

关键词： Hepatocellular Cancer End Stage Liver Disease Transplantation Allocation systems Liver Transplantation human-centered computing Polystyrenes Patients

来源：评论

学校读者我要写书评

暂无评论

Successful Curative Extracorporeal Hepatic Resection for Far-Advanced Hepatocellular Carcinoma in an Adolescent Patient

引用

LIVER TRANSPLANTATION 2010年第5期16卷 685-687页

作者： Sugimachi, Keishi Shirabe, Ken Taketomi, Akinobu Soejima, Yuji Yoshizumi, Tomoharu Yamashita, Yo-Ichi Umeda, Kenji Morita, Kazutoyo Maehara, Yoshihiko Kyushu Univ Grad Sch Med Sci Dept Surg & Sci Higashi Ku Fukuoka 8128582 Japan

Hepatectomy is the principal treatment for hepatocellular carcinoma (HCC); however, some HCCs are not resectable by conventional hepatic resection. In such apparently incurable cases, extracorporeal hepatic resection (ECHR) may offer an option for survival.1 We recently encountered a juvenile patient with faradvanced HCC who was successfully treated by ECHR with favorable long-term survival.

关键词： Successful Extracorporeal Hepatic Hepatectomy Hepatic Organ System human-centered computing ectomy

来源：评论

学校读者我要写书评

暂无评论

Knockdown of Thrombomodulin Enhances HCC Cell Migration through Increase of ZEB1 and Decrease of E-cadherin Gene Expression

引用

ANNALS OF SURGICAL ONCOLOGY 2010年第12期17卷 3379-3385页

作者： Huang, Ming-Te Wei, Po-Li Liu, Jun-Jen Liu, Der-Zen Huey-Chun, Huang An, Jane Wu, Cheng-Chia Wu, Chih-Hsiung Ho, Yuan-Soon Yang, Yi-Yuan Chang, Yu-Jia Taipei Med Univ Dept Surg Taipei Taiwan Taipei Med Univ Shuang Ho Hosp Dept Surg Taipei Taiwan Taipei Med Univ Grad Inst Biomed Technol Taipei Taiwan Taipei Med Univ Grad Inst Biomed Mat & Engn Taipei Taiwan China Med Univ Dept Med Lab Sci & Biotechnol Coll Hlth Care Taichung Taiwan New York Med Coll Valhalla NY 10595 USA Taipei Med Univ Ctr Excellence Canc Res Taipei Taiwan Taipei Med Univ Grad Inst Clin Med Taipei Taiwan

Thrombomodulin (TM) is a key molecule mediating circulation homeostasis through its binding to thrombin. The TM-thrombin complex can activate protein C and thrombin-activatable fibrinolysis inhibitor to form a tight clot. In many cancer tissues, decrease of TM expression may correlate with cancer metastasis. However, the role of TM in hepatocellular carcinoma (HCC) progression is still unclear. We characterized TM expression in HCC cells (HepJ5 and skHep-1 cells) using real-time polymerase chain reaction (PCR) and Western blotting. We then manipulated TM expression using both TM-specific short hairpin RNA (shRNA) and overexpressing it in HCC cells. Transwell migration assay was performed to monitor the migratory ability of HCC cells under different levels of TM expression. We found that TM was ectopically highly expressed in skHep-1 at both transcriptional and translational levels. After silencing TM expression in skHep-1 cells, we found that metastatic capability was dramatically increased. Conversely, overexpression of TM in HepJ5 cells decreased metastatic ability. We investigated the possible mechanism and found that decreased TM-mediated enhancement of cell migration was dependent on upregulation of ZEB1, a repressor of E-cadherin. TM may be a modulator of cancer metastasis in HCC. Downregulation of TM expression may increase ZEB1 and decrease E-cadherin levels.

关键词： Cell Locomotion Zinc Finger E-box-Binding Homeobox 1 Thrombomodulin Neoplasm Metastasis thulium human-centered computing Cell Migration

来源：评论

学校读者我要写书评

暂无评论

The Milan Criteria: No Room on the Metro for the King?

引用

LIVER TRANSPLANTATION 2010年第3期16卷 252-255页

作者： Marsh, J. Wallis Schmidt, Carl Univ Pittsburgh Sch Med Dept Surg Thomas E Starzl Transplantat Inst Pittsburgh PA 15213 USA Ohio State Univ Med Ctr Dept Surg Columbus OH 43210 USA

The incidence of hepatocellular carcinoma (HCC) continues to rise worldwide, and this is related primarily to the prevalence of viral hepatitis.1 Even though the majority of patients with HCC present too late in the course of the disease to be considered for anything other than medical/palliative therapy, there remains a small group of patients who are candidates for potentially curative therapy [liver transplantation (LT), liver resection, or cytoreductive therapy]. Fortunately, there is no absolute resource barrier to liver resection or cytoreductive therapies; however, the same is not true for LT.

关键词： Milan Criteria Room Level Trigger Small groups Subways Hepatectomy human-centered computing Medicine

来源：评论

学校读者我要写书评

暂无评论

Hepatocellular carcinoma: a global view

引用

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY 2010年第8期7卷 448-458页

作者： Yang, Ju Dong Roberts, Lewis R. Mayo Clin Coll Med Miles & Shirley Fiterman Ctr Digest Dis Rochester MN 55905 USA

Hepatocellular carcinoma (HCC) is a global health problem, although developing countries are disproportionally affected: over 80% of HCCs occur in such regions. About three-quarters of HCCs are attributed to chronic HBV and HCV infections. In areas endemic for HCV and HBV, viral transmission occurs at an early age, and infected individuals develop HCC in mid-adulthood. As these are their most productive years of life, HCC accounts for a substantial burden on the health-care system and drain of productive capacity in the low-income and middle-income countries most affected by HCV and HBV infections. Environments with disparate resource levels require different strategies for the optimal management of HCC. In high-resource environments, guidelines from the American Association for the Study of Liver Diseases or European Association for the Study of the Liver should be applied. In intermediate-resource or low-resource environments, the fundamental focus should be on primary prevention of HCC, through universal HBV vaccination, taking appropriate precautions and antiviral treatments. In intermediate-resource and low-resource environments, the infrastructure and capacity for abdominal ultrasonography, percutaneous ethanol injection, radiofrequency ablation and surgical resection should be established. Programs to provide targeted therapy at low cost, similar to the approach used for HIV therapy in the developing world, should be pursued.

关键词： Primary Prevention Global Health HIV therapy Molecular Targeted Therapy Hepatitis B virus Production capacity Liver Diseases human-centered computing European association

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：